Ueda, Seiji

Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure

Usui, M., Matsuoka, H., Miyazaki, H., Ueda, S., Okuda, S., & Imaizumi, T. (1998) · Life Sciences

Nitric Oxide and Endothelin EffectsHeart Failure Treatment and Management

Cited by 232

Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients

Fukami, K., Yamagishi, S.-I., Sakai, K., Kaida, Y., Yokoro, M., Ueda, S., Wada, Y., Takeuchi, M., Shimizu, M., Yamazaki, H., et al. (2015) · Journal of Cardiovascular Pharmacology

Dialysis and Renal Disease ManagementMetabolism and Genetic Disorders

Cited by 84

Asymmetric dimethylarginine (ADMA) is a novel emerging risk factor for cardiovascular disease and the development of renal injury in chronic kidney disease

Ueda, S., Yamagishi, S.-I., Matsumoto, Y., Fukami, K., & Okuda, S. (2007) · Clinical and Experimental Nephrology

Nitric Oxide and Endothelin EffectsCancer-related gene regulation

Cited by 65

Positive association of serum levels of advanced glycation end products and high mobility group box–1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients

Nakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Ueda, Y., Suzuki, T., Yamada, S., Takeuchi, M., Fukami, K., Ueda, S., et al. (2009) · Metabolism

Advanced Glycation End Products researchChronic Kidney Disease and Diabetes

Cited by 53

Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock

Nakamura, T., Sato, E., Fujiwara, N., Kawagoe, Y., Suzuki, T., Ueda, Y., Yamada, S., Shoji, H., Takeuchi, M., Ueda, S., et al. (2009) · Pharmacological Research

Advanced Glycation End Products researchSepsis Diagnosis and Treatment

Cited by 46